AspenBio Completes Clinical Study Patient Enrollment For AppyScore - First Blood-Based Diagnostic Test For Human Appendicitis

AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for humans and animals, reported its FDA 510(k) clinical trial for AppyScore(TM), the world’s first blood-based diagnostic test for human appendicitis, has reached the 800 patient (study “subjects”) target and thereby has officially concluded enrollment in the study.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on December 11th, 2008